Francis Lo Sells 39,741 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 39,741 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $17.49, for a total value of $695,070.09. Following the completion of the sale, the insider directly owned 250,934 shares in the company, valued at $4,388,835.66. This trade represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total value of $340,039.48.
• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.08, for a total value of $430,749.44.

Adaptive Biotechnologies Trading Up 4.0%

Adaptive Biotechnologies stock opened at $17.36 on Wednesday. The business’s fifty day simple moving average is $14.32 and its two-hundred day simple moving average is $15.66. Adaptive Biotechnologies Corporation has a 12 month low of $9.90 and a 12 month high of $20.76. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -52.61 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same period in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Invesco Ltd. boosted its stake in Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. TD Cowen upped their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Guggenheim reiterated a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.